Article
Prolactin activates ERα in the absence of ligand in female mammary development and carcinogenesis in vivo.
Endocrinology - 1 Dec 2013
O'Leary Kathleen A, Jallow Fatou, Rugowski Debra E, Sullivan Ruth, Sinkevicius Kerstin W, Greene Geoffrey L, Schuler Linda A
Abstract excerpt
Resistance of estrogen receptor positive (ERα+) breast cancers to antiestrogens is a major factor in the mortality of this disease. Although activation of ERα in the absence of ligand is hypothesized to contribute to this resistance, the potency of this mechanism in vivo is not clear. Epidemiologic studies have strongly linked prolactin (PRL) to both development of ERα+ breast cancer and resistance to endocrine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.